
|Articles|April 6, 2007
New OAB therapies are on the way
With seven approved drugs for overactive bladder already on the market, the potential for new treatments might seem to be limited. The reality is that OAB treatment is still not optimal.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
4
Optimizing care for men with overactive bladder, with Keith Xavier, MD
5








